Neuroprotective Effects of Puerarin on 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine induced Parkinson's Disease Model in Mice. (20th March 2013)

• Record Type: Journal Article
• Authors: Zhu, Guoqi; Wang, Xuncui; Wu, Shengbing; Li, Xiaoxiang; Li, Qinglin
• Is Part Of: Phytotherapy research. Volume 28:Number 2(2014:Feb.)
• Page Start: 179
• Page End: 186
• Publication Date: 2013-03-20
• Subjects: Materia medica, Vegetable -- Periodicals; Botany, Medical -- Periodicals; Medicinal plants -- Periodicals; Plant Extracts -- therapeutic use -- Periodicals; Plants, Medicinal -- Periodicals; 581.634
• DOI: 10.1002/ptr.4975
• Languages: English
• ISSNs: 0951-418X

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Puerarin, an active component of <italic>Pueraria montana</italic> var. <italic>lobata</italic> (Willd.) Sanjappa &amp; Pradeep is well‐known for its anti‐oxidative and neuroprotective activities. Although anti‐Parkinson's disease activity of puerarin was reported in both of <italic>in vivo</italic> and <italic>in vitro</italic> model, detailed mechanisms are not clarified. In this study, we addressed that puerarin attenuated 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine (MPTP)‐induced behavioral deficits, dopaminergic neuronal degeneration and dopamine depletion. Puerarin administration enhanced glutathione (GSH) activity, glial cell line‐derived neurotrophic factor (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection‐induced progressive elevation of reactive oxygen species (ROS) formation in mice. In addition to the effect on ROS, puerarin ameliorated MPTP‐reduced lysosome‐associated membrane protein type 2A (Lamp 2A) expression. Taken together, our data demonstrate that puerarin attenuates MPTP‐induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K/Akt pathway and GSH activation, which subsequently ameliorate MPTP‐induced ROS formation and decrease of Lamp 2A expression. Copyright © 2013 John Wiley &amp; Sons, Ltd.</p> </abstract>